Also known as: Vyleesi
A melanocortin agonist that increases sexual desire through the brain rather than blood flow.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Activates MC4 receptors in the hypothalamus, which drive desire and arousal.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Libido & sexual function | A | Approved for this use or large randomized trials |
At a glance
- Route
- Subcutaneous, as needed
- Half-life
- About 2.7 hours
Reported dosing
Label: 1.75 mg SC, no more than 1 dose per 24 hours and 8 per month.
Timing: At least 45 minutes before sexual activity.
Cycle: As needed only.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Nausea (about 40% at first dose)
- Flushing, headache
- Temporary rise in blood pressure
- Darkening of skin patches with frequent use
Who should avoid it
- Uncontrolled high blood pressure
- Heart disease
Often combined with
Do not combine with Melanotan II.
Key findings
Approved for premenopausal women with low desire (HSDD). Trials in men with erectile dysfunction showed effect but were not pursued.
Where it is legal (Oct 2026)
| US | Prescription |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open PT-141 (Bremelanotide) in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.